These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34459375)

  • 1. The Use of Lectins as Tools to Combat SARS-CoV-2.
    Martinez D; Amaral D; Markovitz D; Pinto L
    Curr Pharm Des; 2021; 27(41):4212-4222. PubMed ID: 34459375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo.
    Chan JF; Oh YJ; Yuan S; Chu H; Yeung ML; Canena D; Chan CC; Poon VK; Chan CC; Zhang AJ; Cai JP; Ye ZW; Wen L; Yuen TT; Chik KK; Shuai H; Wang Y; Hou Y; Luo C; Chan WM; Qin Z; Sit KY; Au WK; Legendre M; Zhu R; Hain L; Seferovic H; Tampé R; To KK; Chan KH; Thomas DG; Klausberger M; Xu C; Moon JJ; Stadlmann J; Penninger JM; Oostenbrink C; Hinterdorfer P; Yuen KY; Markovitz DM
    Cell Rep Med; 2022 Oct; 3(10):100774. PubMed ID: 36195094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant lectins as versatile tools to fight coronavirus outbreaks.
    Simplicien M; Pério P; Sudor J; Barre A; Benoist H; Van Damme EJM; Rougé P
    Glycoconj J; 2023 Feb; 40(1):109-118. PubMed ID: 36418811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Antiviral Activity of the Lectin Griffithsin against SARS-CoV-2 Is Enhanced by the Presence of Structural Proteins.
    Bains A; Fischer K; Guan W; LiWang PJ
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
    Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
    Front Immunol; 2021; 12():763460. PubMed ID: 35003077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.
    Ahmed MN; Jahan R; Nissapatorn V; Wilairatana P; Rahmatullah M
    Biomed Pharmacother; 2022 Feb; 146():112507. PubMed ID: 34891122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lectins and lectibodies: potential promising antiviral agents.
    Nabi-Afjadi M; Heydari M; Zalpoor H; Arman I; Sadoughi A; Sahami P; Aghazadeh S
    Cell Mol Biol Lett; 2022 May; 27(1):37. PubMed ID: 35562647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
    Kim CH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression.
    Sheehan SA; Hamilton KL; Retzbach EP; Balachandran P; Krishnan H; Leone P; Lopez-Gonzalez M; Suryavanshi S; Kumar P; Russo R; Goldberg GS
    Exp Cell Res; 2021 Jun; 403(1):112594. PubMed ID: 33823179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible Inactivation of SARS-CoV-2 by Lectin Engagement with Two Glycan Clusters on the Spike Protein.
    Nangarlia A; Hassen FF; Canziani G; Bandi P; Talukder C; Zhang F; Krauth D; Gary EN; Weiner DB; Bieniasz P; Navas-Martin S; O'Keefe BR; Ang CG; Chaiken I
    Biochemistry; 2023 Jul; 62(14):2115-2127. PubMed ID: 37341186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensing the interactions between carbohydrate-binding agents and
    Lokhande KB; Apte GR; Shrivastava A; Singh A; Pal JK; K Venkateswara Swamy ; Gupta RK
    J Biomol Struct Dyn; 2022 Jun; 40(9):3880-3898. PubMed ID: 33292056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Klevanski M; Kim H; Heilemann M; Kuner T; Bartenschlager R
    Antiviral Res; 2024 May; 225():105856. PubMed ID: 38447646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting spike glycans to inhibit SARS-CoV2 viral entry.
    Guseman AJ; Rennick LJ; Nambulli S; Roy CN; Martinez DR; Yang DT; Bhinderwala F; Vergara S; Schaefer A; Baric RS; Ambrose Z; Duprex WP; Gronenborn AM
    Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2301518120. PubMed ID: 37695910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycomimetic ligands block the interaction of SARS-CoV-2 spike protein with C-type lectin co-receptors.
    Pollastri S; Delaunay C; Thépaut M; Fieschi F; Bernardi A
    Chem Commun (Camb); 2022 Apr; 58(33):5136-5139. PubMed ID: 35380569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.